Key facts

Home / Investor relations / Key facts

Financial results (Full-year 2023)

Total Revenue

Changes at constant exchange rates

Core Earnings per Share

Changes at constant exchange rates



SEC filings

SEC filings are those documents that we are required to file by virtue of our listing on Nasdaq. They contain mainly financial information.

These documents are also available for viewing on the SEC website at www.sec.gov. The Company will send any holder of the Company’s securities, upon request, a hard copy of the Company’s complete audited financial statements free of charge. Requests may be made by writing to:

Company Secretary
AstraZeneca PLC
1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge CB2 0AA


Our pipeline

Our pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development.

178

projects in our pipeline

17

new molecular entities in our late-stage pipeline

3

new molecular entities under review


Contact us


Investor enquiries

Main Contacts

Andy Barnett

Andy Barnett

Head of Investor Relations

Isabel Gibson

Isabel Gibson

Oncology

Christer Gruvris

Christer Gruvris

BioPharmaceuticals
(Cardiovascular, Renal and Metabolism),
Finance & Fixed Income

Rachel Korolyshun

Rachel Korolyshun

Rare Disease,
Environment, Social and Governance

Morgan Sanford

Morgan Sanford

Oncology

Philip Sparks

Philip Sparks

BioPharmaceuticals
(Respiratory & Immunology, Vaccines & Immune Therapies)

Lauren Swales

Lauren Swales

Rare Disease,
Environment, Social and Governance

Shareholder Helpline


  • Annual reports

    Our Annual Report provides a wide range of information about our global business.


  • Our Pipeline

    Our pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development